Lung neuroendocrine neoplasm
Therapeutic area
Endocrinology
Rare disease
No
- Definition
- A low, intermediate, or high grade malignant neoplasm with neuroendocrine differentiation that arises from the lung. This category includes typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma, large cell neuroendocrine carcinoma, and combined carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Lung neuroendocrine neoplasm
- Therapeutic area
- Endocrinology
- lung neuroendocrine neoplasm
- Advanced Lung Neuroendocrine Tumor
- Locally Advanced Lung Neuroendocrine Neoplasm
- lung NET
- lung neuroendocrine tumor
- lung neuroendocrine tumor, well differentiated, low or intermediate grade
- lung neuroendocrine tumour
- Metastatic Lung Neuroendocrine Neoplasm
- Metastatic Lung Neuroendocrine Tumor
- neuroendocrine neoplasm of lung
- neuroendocrine neoplasm of the lung
- pulmonary neuroendocrine neoplasm
- Pulmonary Neuroendocrine Tumor
- Pulmonary Neuroendocrine Tumors
- Recurrent Lung Neuroendocrine Neoplasm
- Unresectable Lung Neuroendocrine Neoplasm
- Unresectable Lung Neuroendocrine Tumor
- pulmonary neuroendocrine tumour
- Severity
- Severe
- Endocrinology
- Oncology
- Pulmonology
Sources for recorded values
- MONDO ID
- MONDO:0005454
- Parent condition
- MONDO:0019496
Related records
Broader conditions (16)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine gland neoplasm
- Endocrine system disorder
- Human disease
- Lower respiratory tract disorder
- Lung disorder
- Lung neoplasm
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Neuroendocrine neoplasm
- Respiratory system disorder
- Respiratory tract neoplasm
Narrower conditions (9)
- Combined lung carcinoma
- Combined small cell lung carcinoma
- Lung carcinoid tumor
- Lung combined large cell neuroendocrine carcinoma
- Lung combined type small cell adenocarcinoma
- Lung mixed small cell and squamous cell carcinoma
- Occult small cell lung carcinoma
- Pulmonary large cell neuroendocrine carcinoma
- Small cell lung carcinoma
Trials (1)
Approved drugs (1)
Drugs in development (18)
- Adebrelimab Phase 2
- Cabozantinib Phase 2
- Capecitabine Phase 2
- Carboplatin Phase 2
- Durvalumab Phase 2
- Etoposide Phase 2
- Lutetium LU 177 zadavotide guraxetan Phase 1
- Lutetium LU-177 vipivotide tetraxetan Phase 1
- Lutetium LU177 edotreotide Phase 2
- Lutetium oxodotreotide LU-177 Phase 1
- Nendratareotide uzatansine Phase 1
- Nivolumab Phase 1
- Ribociclib Phase 2
- Rivoceranib Phase 2
- Selinexor Phase 2
- Surufatinib Phase 2
- Temozolomide Phase 2
- Tremelimumab Phase 2